专利决战千亿抗体江湖：和铂守垒，百奥赛图朋友圈怒问“挡财路？”

Core Viewpoint - The patent dispute between Heptares Therapeutics and Baidu Biotech has intensified following a decision by the National Intellectual Property Administration of China to uphold Heptares' core patent related to fully human heavy chain antibodies, which supports Heptares' claims against Baidu's RenNano platform [1][2]. Group 1: Patent Dispute Details - On June 5, the National Intellectual Property Administration decided to maintain the validity of Heptares' core patent (patent number: CN201210057668.0), which is crucial for the production of fully human heavy chain antibodies using transgenic animals [1]. - Baidu Biotech's founder publicly expressed confusion and frustration regarding Heptares' legal actions, questioning why Heptares did not pursue similar technology platforms like RenMab and RenLite [1][2]. - Baidu Biotech announced plans to evaluate legal options to defend its rights, emphasizing that previous jurisdictional challenges were procedural and that the substantive case has yet to be heard [1]. Group 2: Broader Industry Implications - The patent battle reflects deeper issues within China's innovative pharmaceutical industry, highlighting the critical importance of intellectual property protection amid rapid industry growth [2]. - Heptares is also involved in ongoing patent litigation in the U.S. against Teneobio, which was acquired by Amgen for $2.5 billion, indicating the complexities and challenges faced by Chinese pharmaceutical companies in global intellectual property rights enforcement [2]. - The situation raises questions about balancing the protection of essential technologies with maintaining an open and cooperative industry ecosystem, as well as defining the boundaries between reasonable protection and excessive monopolization [2].